|
Dexcom Issues Updated Device Correction Notice for G6 and G7 Receivers Following FDA Recall
|
Written by: J. Smith |
Hits: 576
|
|
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
|
Written by: J. Smith |
Hits: 800
|
|
Insulet Launches Omnipod 5 iPhone App with Dexcom G7 Integration for All U.S. Users
|
Written by: J. Smith |
Hits: 503
|
|
Denmark Launches Ambitious Heart Disease Study with Record-Breaking Grant
|
Written by: J. Smith |
Hits: 585
|
|
Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial
|
Written by: J. Smith |
Hits: 866
|
|
Large U.S. Study Finds No Increased Risk of Vision Loss from Semaglutide
|
Written by: J. Smith |
Hits: 940
|
|
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
|
Written by: J. Smith |
Hits: 1698
|
|
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
|
Written by: J. Smith |
Hits: 1300
|
|
Lilly’s Oral GLP-1 Clears Key Trial as Pfizer Exits Race
|
Written by: J. Smith |
Hits: 746
|
|
FDA and Novo Nordisk Warn of Counterfeit Ozempic in U.S. Supply Chain
|
Written by: J. Smith |
Hits: 902
|
